Series B · Biotech · Leiden, Netherlands · Founded 2020 · 51–200 employees
Leyden Labs is a Dutch clinical-stage biotechnology company developing novel broadly protective nasal sprays and mucosal immunity therapies aimed at preventing respiratory virus infections — its lead PanFlu program uses intranasally delivered broadly neutralising antibodies to block viruses like influenza and coronaviruses at their entry point, advancing global pandemic preparedness and respiratory health; backed by strong international investors and significant European funding to scale clinical development.